Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.

Mboge MY, Chen Z, Khokhar D, Wolff A, Ai L, Heldermon CD, Bozdag M, Carta F, Supuran CT, Brown KD, McKenna R, Frost CJ, Frost SC.

Biochem J. 2019 May 28;476(10):1497-1513. doi: 10.1042/BCJ20190177.

PMID:
31072911
2.

A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.

Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK.

Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4.

PMID:
30718919
3.

Projected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastases.

O'Dell W, Takita C, Casey-Sawicki K, Daily K, Heldermon CD, Okunieff P.

Breast J. 2019 Jan;25(1):75-79. doi: 10.1111/tbj.13153. Epub 2018 Dec 12.

PMID:
30548515
4.

Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti.

DeGennaro V Jr, Jiwani F, Patberg E, Gibbs M, Libby R, Gabriel D, Heldermon CD, Daily K, Bernard J Jr.

J Glob Oncol. 2018 Sep;4:1-9. doi: 10.1200/JGO.17.00135.

5.

Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.

Chen Z, Ai L, Mboge MY, Tu C, McKenna R, Brown KD, Heldermon CD, Frost SC.

PLoS One. 2018 Jul 2;13(7):e0199476. doi: 10.1371/journal.pone.0199476. eCollection 2018.

6.

UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system.

Chen Z, Ai L, Mboge MY, McKenna R, Frost CJ, Heldermon CD, Frost SC.

Cancer Biol Ther. 2018 Jul 3;19(7):598-608. doi: 10.1080/15384047.2018.1449612. Epub 2018 Apr 13.

7.
8.

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.

Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952.

9.

Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.

Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, Chang LJ, Lu J.

J Clin Invest. 2016 Nov 1;126(11):4174-4186. doi: 10.1172/JCI86623. Epub 2016 Oct 10.

10.

Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.

Bloom MD, Gibney JM, Heldermon CD.

Cancer Treat Commun. 2016;7:1-3. No abstract available.

11.

Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes.

Gilkes JA, Bloom MD, Heldermon CD.

Mol Genet Metab Rep. 2015 Dec 7;6:48-54. doi: 10.1016/j.ymgmr.2015.11.006. eCollection 2016 Mar.

12.

Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.

Gilkes JA, Bloom MD, Heldermon CD.

Gene Ther. 2016 Mar;23(3):263-71. doi: 10.1038/gt.2015.111. Epub 2015 Dec 16.

13.

High resolution functional photoacoustic tomography of breast cancer.

Li X, Heldermon CD, Yao L, Xi L, Jiang H.

Med Phys. 2015 Sep;42(9):5321-8. doi: 10.1118/1.4928598.

PMID:
26328981
14.

A phase I study of thymoglobulin for relapsed or refractory multiple myeloma.

Keller J, Fiala MA, Dipersio J, Stockerl-Goldstein K, Vij R, Heldermon CD.

Leuk Lymphoma. 2016 Feb;57(2):453-455. doi: 10.3109/10428194.2015.1049170. Epub 2015 Jun 19. No abstract available.

PMID:
25971909
15.

Novel agents that downregulate EGFR, HER2, and HER3 in parallel.

Ferreira RB, Law ME, Jahn SC, Davis BJ, Heldermon CD, Reinhard M, Castellano RK, Law BK.

Oncotarget. 2015 Apr 30;6(12):10445-59.

16.

Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.

Gilkes JA, Heldermon CD.

Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:133-40. Review.

PMID:
25345095
17.

TRIM29 suppresses TWIST1 and invasive breast cancer behavior.

Ai L, Kim WJ, Alpay M, Tang M, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, Brown KD.

Cancer Res. 2014 Sep 1;74(17):4875-87. doi: 10.1158/0008-5472.CAN-13-3579. Epub 2014 Jun 20.

18.

Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.

Kolarich AR, Reynolds BA, Heldermon CD.

Acta Oncol. 2014 Oct;53(10):1434-6. doi: 10.3109/0284186X.2014.920959. Epub 2014 May 19. No abstract available.

PMID:
24834794
19.

Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.

Heldermon CD, Qin EY, Ohlemiller KK, Herzog ED, Brown JR, Vogler C, Hou W, Orrock JL, Crawford BE, Sands MS.

Gene Ther. 2013 Sep;20(9):913-21. doi: 10.1038/gt.2013.14. Epub 2013 Mar 28.

20.

Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Heldermon CD, Ohlemiller KK, Herzog ED, Vogler C, Qin E, Wozniak DF, Tan Y, Orrock JL, Sands MS.

Mol Ther. 2010 May;18(5):873-80. doi: 10.1038/mt.2010.17. Epub 2010 Feb 23.

21.

Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B.

Heldermon CD, Hennig AK, Ohlemiller KK, Ogilvie JM, Herzog ED, Breidenbach A, Vogler C, Wozniak DF, Sands MS.

PLoS One. 2007 Aug 22;2(8):e772.

22.

Site-directed mutation of conserved cysteine residues does not inactivate the Streptococcus pyogenes hyaluronan synthase.

Heldermon CD, Tlapak-Simmons VL, Baggenstoss BA, Weigel PH.

Glycobiology. 2001 Dec;11(12):1017-24.

Supplemental Content

Loading ...
Support Center